{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:23:13Z","timestamp":1778617393803,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R21 AG056028"],"award-info":[{"award-number":["R21 AG056028"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RF1 AG054160"],"award-info":[{"award-number":["RF1 AG054160"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RF1 AG058188"],"award-info":[{"award-number":["RF1 AG058188"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01 NS092615"],"award-info":[{"award-number":["R01 NS092615"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010302","name":"Robert A. and Renee E. Belfer Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ymthe.2021.02.026","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T05:06:02Z","timestamp":1614402362000},"page":"2294-2307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Gene therapy using A\u03b2 variants for amyloid reduction"],"prefix":"10.1016","volume":"29","author":[{"given":"Kyung-Won","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SaeWoong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas L.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna L.","family":"Jankowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.02.026_bib1","unstructured":"Biogen Plans Regulatory Filing for Aducanumab in Alzheimer\u2019s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies. Globe Newswire, October 22, 2019. https:\/\/www.globenewswire.com\/news-release\/2019\/10\/22\/1933045\/0\/en\/Biogen-Plans-Regulatory-Filing-for-Aducanumab-in-Alzheimer-s-Disease-Based-on-New-Analysis-of-Larger-Dataset-from-Phase-3-Studies.html."},{"key":"10.1016\/j.ymthe.2021.02.026_bib2","unstructured":"FDA Advisory Committee Throws Cold Water on Aducanumab Filing. Alzforum, Networking for a Cure, November 6, 2020. https:\/\/www.alzforum.org\/news\/community-news\/fda-advisory-committee-throws-cold-water-aducanumab-filing."},{"key":"10.1016\/j.ymthe.2021.02.026_bib3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cmdc.201500215","article-title":"Perspectives on Inhibiting \u03b2-Amyloid Aggregation through Structure-Based Drug Design","volume":"10","author":"Mishra","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ymthe.2021.02.026_bib4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0798-822","article-title":"Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer\u2019s therapy","volume":"4","author":"Soto","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2021.02.026_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874070701105010039","article-title":"Short Peptides as Inhibitors of Amyloid Aggregation","volume":"5","author":"Neddenriep","year":"2011","journal-title":"Open Biotechnol. J."},{"key":"10.1016\/j.ymthe.2021.02.026_bib6","doi-asserted-by":"crossref","first-page":"30990","DOI":"10.1074\/jbc.M114.589069","article-title":"Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein","volume":"289","author":"Maloney","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.02.026_bib7","doi-asserted-by":"crossref","first-page":"30977","DOI":"10.1074\/jbc.M114.599027","article-title":"The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-\u03b2 (A\u03b2) aggregation","volume":"289","author":"Benilova","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.02.026_bib8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2021.02.026_bib9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.1168979","article-title":"A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis","volume":"323","author":"Di Fede","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.02.026_bib10","doi-asserted-by":"crossref","first-page":"20949","DOI":"10.1038\/srep20949","article-title":"Tackling amyloidogenesis in Alzheimer\u2019s disease with A2V variants of Amyloid-\u03b2","volume":"6","author":"Di Fede","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2021.02.026_bib11","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/acschemneuro.5b00171","article-title":"Amyloid \u03b2-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer\u2019s Disease Mutation","volume":"6","author":"Zheng","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/acscombsci.6b00116","article-title":"Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-\u03b2 (A\u03b2) Aggregation: Potential Therapeutics of Alzheimer\u2019s Disease","volume":"19","author":"Goyal","year":"2017","journal-title":"ACS Comb. Sci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/mp400680d","article-title":"Strategies to deliver peptide drugs to the brain","volume":"11","author":"Lalatsa","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ymthe.2021.02.026_bib14","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.0.CO;2-E","article-title":"Beta-sheet breaker peptide inhibitor of Alzheimer\u2019s amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma","volume":"39","author":"Poduslo","year":"1999","journal-title":"J.\u00a0Neurobiol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib15","doi-asserted-by":"crossref","first-page":"E4976","DOI":"10.1073\/pnas.1600749113","article-title":"Atomic-resolution structure of a disease-relevant A\u03b2(1-42) amyloid fibril","volume":"113","author":"W\u00e4lti","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.02.026_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1126\/science.aao2825","article-title":"Fibril structure of amyloid-\u03b2(1-42) by cryo-electron microscopy","volume":"358","author":"Gremer","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2021.02.026_bib17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nsmb.2991","article-title":"A\u03b2(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer\u2019s disease","volume":"22","author":"Xiao","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1529\/biophysj.106.091017","article-title":"Molecular alignment within beta-sheets in Abeta(14-23) fibrils: solid-state NMR experiments and theoretical predictions","volume":"92","author":"Bu","year":"2007","journal-title":"Biophys. J."},{"key":"10.1016\/j.ymthe.2021.02.026_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jmb.2003.11.008","article-title":"Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis","volume":"335","author":"Williams","year":"2004","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib20","doi-asserted-by":"crossref","first-page":"52781","DOI":"10.1074\/jbc.M406262200","article-title":"Analysis of the secondary structure of beta-amyloid (Abeta42) fibrils by systematic proline replacement","volume":"279","author":"Morimoto","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.02.026_bib21","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1021\/ja044531p","article-title":"Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloform","volume":"127","author":"Bernstein","year":"2005","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2021.02.026_bib22","doi-asserted-by":"crossref","first-page":"25333","DOI":"10.1074\/jbc.M312710200","article-title":"Presenilin 1 stabilizes the C-terminal fragment of the amyloid precursor protein independently of gamma-secretase activity","volume":"279","author":"Pitsi","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.02.026_bib23","doi-asserted-by":"crossref","first-page":"6732","DOI":"10.1523\/JNEUROSCI.16-21-06732.1996","article-title":"Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein","volume":"16","author":"Oster-Granite","year":"1996","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00401-016-1577-6","article-title":"Intraneuronal aggregation of the \u03b2-CTF fragment of APP (C99) induces A\u03b2-independent lysosomal-autophagic pathology","volume":"132","author":"Lauritzen","year":"2016","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib25","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1523\/JNEUROSCI.0578-19.2019","article-title":"Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-\u03b2CTF (C99)","volume":"39","author":"Jiang","year":"2019","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib26","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jbiotec.2006.11.026","article-title":"The level of synthesis and secretion of Gaussia princeps luciferase in transfected CHO cells is heavily dependent on the choice of signal peptide","volume":"128","author":"Knappskog","year":"2007","journal-title":"J.\u00a0Biotechnol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/ejn.12126","article-title":"Viral transduction of the neonatal brain delivers controllable genetic mosaicism for visualising and manipulating neuronal circuits in\u00a0vivo","volume":"37","author":"Kim","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/hmg\/ddh019","article-title":"Mutant presenilins specifically elevate the levels of the 42 residue \u03b2-amyloid peptide in\u00a0vivo: evidence for augmentation of a 42-specific \u03b3 secretase","volume":"13","author":"Jankowsky","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2021.02.026_bib29","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2174\/13816128113199990068","article-title":"Inhibition of amyloid-\u03b2 aggregation in Alzheimer\u2019s disease","volume":"20","author":"Wang","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ymthe.2021.02.026_bib30","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1021\/acschemneuro.8b00185","article-title":"Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer\u2019s Disease","volume":"9","author":"Ryan","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1096\/fj.01-0841fje","article-title":"Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer\u2019s disease by treatment with a beta-sheet breaker peptide","volume":"16","author":"Permanne","year":"2002","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2021.02.026_bib32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1021\/cn100057j","article-title":"Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer\u2019s Disease transgenic mice","volume":"1","author":"Aileen Funke","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3233\/JAD-121792","article-title":"Treatment with D3 removes amyloid deposits, reduces inflammation, and improves cognition in aged A\u03b2PP\/PS1 double transgenic mice","volume":"34","author":"van Groen","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ymthe.2021.02.026_bib34","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s12035-018-1209-3","article-title":"A\u03b2 Oligomer Elimination Restores Cognition in Transgenic Alzheimer\u2019s Mice with Full-blown Pathology","volume":"56","author":"Schemmert","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib35","doi-asserted-by":"crossref","first-page":"e54769","DOI":"10.1371\/journal.pone.0054769","article-title":"A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe\/PS1\u0394E9 mouse model of Alzheimer\u2019s disease","volume":"8","author":"Parthsarathy","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.02.026_bib36","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1007\/s00018-013-1314-4","article-title":"Spatial learning impairments in PLB1Triple knock-in Alzheimer mice are task-specific and age-dependent","volume":"70","author":"Ryan","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib37","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1110\/ps.051470405","article-title":"Mutagenic analysis of the nucleation propensity of oxidized Alzheimer\u2019s beta-amyloid peptide","volume":"14","author":"Christopeit","year":"2005","journal-title":"Protein Sci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib38","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1742-4658.2005.05102.x","article-title":"Mutagenesis of the central hydrophobic cluster in Abeta42 Alzheimer\u2019s peptide. Side-chain properties correlate with aggregation propensities","volume":"273","author":"de Groot","year":"2006","journal-title":"FEBS J."},{"key":"10.1016\/j.ymthe.2021.02.026_bib39","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0022-2836(02)00399-6","article-title":"Mutations that reduce aggregation of the Alzheimer\u2019s Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis","volume":"319","author":"Wurth","year":"2002","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib40","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1042\/BCJ20180247","article-title":"An A\u03b242 variant that inhibits intra- and extracellular amyloid aggregation and enhances cell viability","volume":"475","author":"Oren","year":"2018","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymthe.2021.02.026_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gdata.2016.01.003","article-title":"Mutation-based structural modification and dynamics study of amyloid beta peptide (1-42): An in-silico-based analysis to cognize the mechanism of aggregation","volume":"7","author":"Panda","year":"2016","journal-title":"Genom. Data"},{"key":"10.1016\/j.ymthe.2021.02.026_bib42","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1111\/j.1365-2958.1991.tb01964.x","article-title":"Tn7: a target site-specific transposon","volume":"5","author":"Craig","year":"1991","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4155\/tde.14.111","article-title":"Challenges in the delivery of peptide drugs: an industry perspective","volume":"6","author":"Lewis","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ymthe.2021.02.026_bib44","doi-asserted-by":"crossref","first-page":"13905","DOI":"10.1074\/jbc.M211976200","article-title":"Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer\u2019s disease","volume":"278","author":"Adessi","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2021.02.026_bib45","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nbt1117-998","article-title":"First AAV gene therapy poised for landmark approval","volume":"35","author":"Smalley","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene Abeparvovec: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2021.02.026_bib47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.02.026_bib48","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s11689-018-9234-0","article-title":"Recent progress and considerations for AAV gene therapies targeting the central nervous system","volume":"10","author":"Lykken","year":"2018","journal-title":"J.\u00a0Neurodev. Disord."},{"key":"10.1016\/j.ymthe.2021.02.026_bib49","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/v11020102","article-title":"Adeno-associated Virus (AAV) versus Immune Response","volume":"11","author":"Rabinowitz","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2021.02.026_bib50","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41434-018-0028-5","article-title":"More expansive gene transfer to the rat CNS: AAV PHP.EB vector dose-response and comparison to AAV PHP.B","volume":"25","author":"Dayton","year":"2018","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2021.02.026_bib51","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib52","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ymthe.2019.07.017","article-title":"AAV-PHP.B Administration Results in a Differential Pattern of CNS Biodistribution in Non-human Primates Compared with Mice","volume":"27","author":"Liguore","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.02.026_bib53","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","article-title":"Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain","volume":"665","author":"Matsuzaki","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymthe.2021.02.026_bib54","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL\/6J Mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.02.026_bib55","doi-asserted-by":"crossref","first-page":"e0188830","DOI":"10.1371\/journal.pone.0188830","article-title":"Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection","volume":"12","author":"Hammond","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.02.026_bib56","doi-asserted-by":"crossref","first-page":"e76310","DOI":"10.1371\/journal.pone.0076310","article-title":"Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain","volume":"8","author":"Aschauer","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2021.02.026_bib57","first-page":"116","article-title":"Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP.B","volume":"9","author":"Jackson","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41434-020-0169-1","article-title":"Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract: comparison of four promoters","volume":"28","author":"Nieuwenhuis","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2021.02.026_bib59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mcn.2008.02.009","article-title":"Loss of Fyn tyrosine kinase on the C57BL\/6 genetic background causes hydrocephalus with defects in oligodendrocyte development","volume":"38","author":"Goto","year":"2008","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib60","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.expneurol.2009.05.015","article-title":"Characterization of juvenile and young adult mice following induction of hydrocephalus with kaolin","volume":"219","author":"da Silva Lopes","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib61","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.expneurol.2006.02.113","article-title":"Brain damage in neonatal rats following kaolin induction of hydrocephalus","volume":"200","author":"Khan","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib62","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2021.02.026_bib63","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1007\/s13361-019-02350-z","article-title":"High-Throughput Quantitative Top-Down Proteomics: Histone H4","volume":"30","author":"Holt","year":"2019","journal-title":"J.\u00a0Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ymthe.2021.02.026_bib64","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1074\/mcp.M900144-MCP200","article-title":"A mixed integer linear optimization framework for the identification and quantification of targeted post-translational modifications of highly modified proteins using multiplexed electron transfer dissociation tandem mass spectrometry","volume":"8","author":"DiMaggio","year":"2009","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ymthe.2021.02.026_bib65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-0716-0175-4_7","article-title":"Adeno-Associated Virus as Gene Delivery Vehicle into the Retina","volume":"2092","author":"Deng","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib66","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/156652310793797685","article-title":"Production, purification and characterization of adeno-associated vectors","volume":"10","author":"Ayuso","year":"2010","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.02.026_bib67","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4939-3271-9_17","article-title":"Widespread Neuronal Transduction of the Rodent CNS via Neonatal Viral Injection","volume":"1382","author":"Kim","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2021.02.026_bib68","first-page":"51863","article-title":"Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction","author":"Kim","year":"2014","journal-title":"J.\u00a0Vis. Exp."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621001295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621001295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:06:17Z","timestamp":1778616377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621001295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1525001621001295"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.02.026","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy using A\u03b2 variants for amyloid reduction","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.02.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}